208 related articles for article (PubMed ID: 21576449)
1. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
Steed M; Vidaillac C; Rybak MJ
Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
Werth BJ; Barber KE; Ireland CE; Rybak MJ
Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
Steed ME; Vidaillac C; Rybak MJ
Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693
[TBL] [Abstract][Full Text] [Related]
4. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
[TBL] [Abstract][Full Text] [Related]
5. Synergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilms.
Kunz Coyne AJ; Stamper K; Bleick C; Kebriaei R; Lehman SM; Rybak MJ
Microbiol Spectr; 2024 Apr; 12(4):e0321223. PubMed ID: 38411110
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.
Steed ME; Vidaillac C; Winterfield P; Biek D; Rybak MJ
Antimicrob Agents Chemother; 2012 May; 56(5):2691-5. PubMed ID: 22354289
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
Werth BJ; Sakoulas G; Rose WE; Pogliano J; Tewhey R; Rybak MJ
Antimicrob Agents Chemother; 2013 Jan; 57(1):66-73. PubMed ID: 23070161
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
Steed ME; Werth BJ; Ireland CE; Rybak MJ
Antimicrob Agents Chemother; 2012 Nov; 56(11):5709-14. PubMed ID: 22908167
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect".
Werth BJ; Steed ME; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2013 Jun; 57(6):2664-8. PubMed ID: 23545533
[TBL] [Abstract][Full Text] [Related]
10. Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an
Kunz Coyne AJ; Bleick C; Stamper K; Kebriaei R; Bayer AS; Lehman SM; Rybak MJ
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0138823. PubMed ID: 38376187
[TBL] [Abstract][Full Text] [Related]
11. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.
Steed ME; Vidaillac C; Rybak MJ
Antimicrob Agents Chemother; 2010 Dec; 54(12):5187-92. PubMed ID: 20921318
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus.
MacVane SH; So W; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2014 Dec; 58(12):7520-6. PubMed ID: 25288076
[TBL] [Abstract][Full Text] [Related]
14. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
Sader HS; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel AR; Tomaselli S; Bowker KE
Antimicrob Agents Chemother; 2013 Jun; 57(6):2451-6. PubMed ID: 23459495
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
Vidaillac C; Leonard SN; Rybak MJ
Antimicrob Agents Chemother; 2009 Nov; 53(11):4712-7. PubMed ID: 19738009
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
Saravolatz L; Pawlak J; Johnson L
Antimicrob Agents Chemother; 2010 Jul; 54(7):3027-30. PubMed ID: 20404122
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
20. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.
Rose WE; Schulz LT; Andes D; Striker R; Berti AD; Hutson PR; Shukla SK
Antimicrob Agents Chemother; 2012 Oct; 56(10):5296-302. PubMed ID: 22869564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
